Stock Analysis
Ercros (BME:ECR) Full Year 2023 Results
Key Financial Results
- Revenue: €757.6m (down 26% from FY 2022).
- Net income: €28.8m (down 59% from FY 2022).
- Profit margin: 3.8% (down from 6.9% in FY 2022). The decrease in margin was driven by lower revenue.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Ercros Revenues Disappoint
Revenue missed analyst estimates by 2.2%.
Looking ahead, revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Chemicals industry in Europe.
Performance of the market in Spain.
The company's shares are up 11% from a week ago.
Risk Analysis
What about risks? Every company has them, and we've spotted 3 warning signs for Ercros you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Ercros is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BME:ECR
Ercros
Ercros, S.A. manufactures and sells basic chemicals, intermediate chemicals, and pharmaceuticals in Spain.
Excellent balance sheet with reasonable growth potential.
